Market Overview

Hapoalim Securities Reports on BioSpecifics (BSTC)


In a report released today, Hapoalim Securities commented on BioSpecifics (NASDAQ: BSTC). In the report, Hapoalim was bullish on the company.

Hapoalim writes, “BioSpecifics reported 1Q11 EPS of $0.51 versus our $(0.06) estimate and the company anticipates that it will now be profitable on an ongoing annual basis. Based on the recent launch of Xiapex in Europe and sales trends for Xiaflex in the U.S., we are increasing our peak sales estimate for Xiaflex and increasing our Price Target from $26 to $27. We are also upgrading BioSpecifics from a Hold to a Buy.”

Hapoalim has a Buy rating on the company and a price target of $27. Shares of the company closed the trading day at $22.83, up from the opening price of $22.58.


Related Articles (BSTC)

View Comments and Join the Discussion!

Posted-In: BioSpecifics Technologies Corp. Hapoalim SecuritiesAnalyst Color Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at